Breast Cancer Highlights From ASCO 2026: ADCs, Biomarkers, and Earlier Treatment Strategies Take Center Stage
Amol Akhade: What The Devil Wears Prada 2 Taught Me About Oncology?
Alexandre Chan: Real-World Safety of Antibody–Drug Conjugates
Khizra Ahmad: Covering ASCO26 from Front-Row Seat as OncoDaily Ambassador
ESTRO-EORTC Expert Guideline on Target Delineation and Radiotherapy for Stage I–III Small Cell Lung Cancer
Christopher Jackson: If Innovation Is the Heart of Oncology, Then Access Must Be Its Conscience
IMMUNIB Study Uptades: Nivolumab Plus Lenvatinib in Unresectable HCC
Hesham ElGhazaly: Meeting Global Oncology Leaders at ASCO 2026
Identify low-risk febrile neutropenia patients using the MASCC (Multinational Association for Supportive Care in Cancer) risk index.
Check if YES (0 points), leave unchecked if NO (+5 points)
Check if YES (0 points), leave unchecked if NO (+4 points)
Check if YES (0 points), leave unchecked if NO (+3 points)
Check if YES (+3 points), leave unchecked if NO (0 points)
Check if YES (+2 points), leave unchecked if NO (0 points)
MASCC Risk Index Scoring:
Risk Classification:
